Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer. 

Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. 

Lundgren recently served as Senior Vice President, Commercial Portfolio Organization at Genentech (a member of the Roche Group), where he led and oversaw the commercial strategy across all therapeutic areas of the company’s broad portfolio. 

Lundgren, who succeeds Daniel Vitt as CEO, will now oversee the development of vidofludimus in the pivotal Phase III ENSURE programme in relapsing multiple sclerosis (RMS) and the planned Phase III programme in primary progressive multiple sclerosis (PPMS), while also preparing for potential new drug application (NDA) filing, regulatory approval and commercialisation. 

“I am truly honoured to be joining Immunic at such an exciting and pivotal moment,” Lundgren said. 

“Over the past decade, the treatment landscape for MS has advanced meaningfully, broadening what is possible for people living with this complex disease. Yet a large unmet need remains, particularly for treatment options with the potential to slow disability progression and preserve neurological function.  

“Vidofludimus calcium’s potential to treat MS by targeting both immunological and neuroprotective pathways, along with a safety and tolerability profile that appears favourable to date, offers a differentiated approach within the MS therapeutic landscape, with the chance to impact both relapsing and progressive forms of the disease.  

“Having spent my career focused on bringing innovative medicines to patients, including those with MS, I believe Immunic is uniquely positioned to advance this important programme through late-stage development and potential commercialisation. I look forward to working alongside the talented team at Immunic to help realise that vision.”